Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.53 USD | +1.10% | +3.75% | +13.09% |
Apr. 29 | Transcript : Capricor Therapeutics, Inc. - Special Call | |
Apr. 24 | Capricor Therapeutics Gets Another Type-B Meeting With FDA for Duchenne Muscular Dystrophy Investigational Drug | MT |
Financials (USD)
Sales 2024 * | 21.4M | Sales 2025 * | 89.52M | Capitalization | 174M |
---|---|---|---|---|---|
Net income 2024 * | -33M | Net income 2025 * | 8M | EV / Sales 2024 * | 8.14 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.95 x |
P/E ratio 2024 * |
-5.73
x | P/E ratio 2025 * |
56.7
x | Employees | 102 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.66% |
Latest transcript on Capricor Therapeutics, Inc.
1 day | +1.10% | ||
1 week | +3.75% | ||
Current month | +4.93% | ||
1 month | -17.71% | ||
3 months | +38.60% | ||
6 months | +93.70% | ||
Current year | +13.09% |
Managers | Title | Age | Since |
---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 60 | 13-11-19 |
Anthony Bergmann
DFI | Director of Finance/CFO | 38 | 13-11-19 |
Kristi Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Philip Gotwals
BRD | Director/Board Member | 61 | 23-07-20 |
Earl Collier
BRD | Director/Board Member | 76 | 13-11-19 |
George Dunbar
BRD | Director/Board Member | 77 | 13-11-19 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-06 | 5.53 | +1.10% | 140,948 |
24-05-03 | 5.47 | +4.39% | 259,837 |
24-05-02 | 5.24 | -1.69% | 210,194 |
24-05-01 | 5.33 | +1.14% | 171,035 |
24-04-30 | 5.27 | -1.13% | 248,659 |
Delayed Quote Nasdaq, May 06, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.09% | 172M | |
+9.15% | 105B | |
-1.08% | 104B | |
+5.79% | 22.94B | |
-11.55% | 22.34B | |
-7.01% | 19.25B | |
-37.08% | 17.08B | |
-9.91% | 16.96B | |
+7.55% | 14.16B | |
+40.04% | 12.63B |
- Stock Market
- Equities
- CAPR Stock